Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10870559 | 0.90 | MAPT (0.71) | MAPTKDM4EMEN1KMT2AHTT | |
| SCHEMBL11643791 | 0.89 | MAPT (0.78) | MAPTKDM4EMEN1KMT2AHTT | |
| SCHEMBL11439028 | 0.88 | MAPT (0.50) | MAPTKDM4EMEN1KMT2AHTT | |
| SCHEMBL4835421 | 0.86 | MAPT (0.70) | MAPTKDM4EMEN1KMT2AHTT | |
| SCHEMBL1141920 | 0.86 | MAPT (0.70) | MAPTKDM4EMEN1KMT2AHTT | |
| SCHEMBL5453599 | 0.84 | MAPT (0.64) | MAPTKDM4EMEN1KMT2AHTT | |
| SCHEMBL14333508 | 0.84 | MAPT (0.64) | MAPTKDM4EMEN1KMT2AHTT | |
| SCHEMBL16025774 | 0.84 | MAPT (0.64) | MAPTKDM4EMEN1KMT2AHTT | |
| SCHEMBL8746685 | 0.83 | MAPT (0.62) | MAPTKDM4EMEN1KMT2AHTT | |
| SCHEMBL10341874 | 0.83 | MAPT (0.67) | MAPTKDM4EMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48140-E1 | Furanone derivative | CARNA BIOSCIENCES, INC. (JP) | 2020-08-04 | — | — | US | disclosed |
| EP-2692728-B1 | NOVEL FURANONE DERIVATIVE | CARNA BIOSCIENCES INC (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-RE46815-E1 | Furanone derivative | CARNA BIOSCIENCES, INC. (JP) | 2018-05-01 | — | — | US | disclosed |
| US-8742113-B2 | Furanone derivative | SBI BIOTECH CO., LTD. (JP) | 2014-06-03 | — | — | US | disclosed |
| EP-2692728-A1 | NOVEL FURANONE DERIVATIVE | SBI Biotech Co., Ltd. (JP) | 2014-02-05 | — | — | EP | disclosed |
| US-20140018533-A1 | NOVEL FURANONE DERIVATIVE | CARNA BIOSCIENCES, INC. (JP) | 2014-01-16 | — | — | US | disclosed |
| CN-102171190-A | Insecticidal benzenedicarboxamide derivative | BAYER CROPSCIENCE AG | 2011-08-31 | — | — | CN | disclosed |
| US-20110184188-A1 | Insecticidal Benzenedicarboxamide Derivative | BAYER CROPSCIENCE AG (DE) | 2011-07-28 | — | — | US | disclosed |
| EP-2318374-A2 | INSECTICIDAL BENZENEDICARBOXAMIDE DERIVATIVE | Bayer CropScience AG (DE) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010012442-A2 | INSECTICIDAL BENZENEDICARBOXAMIDE DERIVATIVE | BAYER CROPSCIENCE AG (DE) | 2010-02-04 | — | — | WO | disclosed |
| EP-0569380-B1 | ACRIDINE DERIVATIVES | GLAXO LAB SA (FR) | 1997-05-28 | — | — | EP | disclosed |
| US-5604237-A | IMPROVE OR INCREASE EFFICACY OF ANTITUMOR AGENT, INCREASE OR RESTORE SENSITIVITY OF TUMOR TO ANTITUMOR AGENT, REVERSE OR REDUCE RESISTANCE OF TUMOR TO ANTITUMOR AGENT | LABORATOIRES GLAXO SA (FR) | 1997-02-18 | — | — | US | disclosed |
| EP-0494623-A1 | Acridine derivatives | LABORATOIRES GLAXO SA (FR) | 1992-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018533-A1 | NOVEL FURANONE DERIVATIVE | CYP11B1, OXER1, CYP11B2 | MAPT 4591/4885KDM4E 1886/4885MEN1 427/4885 |
| US-20110184188-A1 | Insecticidal Benzenedicarboxamide Derivative | DDT, BRD9, BCL2A1 | MAPT 4079/4885KDM4E 346/4885MEN1 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.